Research location
Greenbrae
California, United States
Advertisement
Research activity in Greenbrae
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 286 trials and 314 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Greenbrae
286 linked trials · page 1 of 6Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related ComorbiditiesNCT07752979 · 2026-08-04 · 1 site observation
RECRUITING
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 · 2026-05-15 · 1 site observation
RECRUITING
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerNCT07214532 · 2026-05-08 · 1 site observation
RECRUITING
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation
RECRUITING
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 · 2025-12-15 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerNCT06793215 · 2025-10-24 · 1 site observation
RECRUITING
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid TumorsNCT06997029 · 2025-08-01 · 1 site observation
RECRUITING
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)NCT06667076 · 2024-12-16 · 1 site observation
RECRUITING
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 · 2023-11-17 · 1 site observation
RECRUITING
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyNCT05646862 · 2023-06-07 · 1 site observation
RECRUITING
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyNCT05774951 · 2023-03-31 · 1 site observation
RECRUITING
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13 · 1 site observation
RECRUITING
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 DiabetesNCT07030868 · 2025-06-19 · 1 site observation
TERMINATED
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06683508 · 2024-11-13 · 1 site observation
COMPLETED
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 · 2024-09-20 · 1 site observation
COMPLETED
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 · 2024-02-05 · 1 site observation
COMPLETED
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)NCT06099782 · 2023-12-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)NCT06065748 · 2023-12-11 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903 · 2023-06-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA StudyNCT05645536 · 2022-12-28 · 1 site observation
ENROLLING_BY_INVITATION
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First TimeNCT05362058 · 2022-06-03 · 1 site observation
COMPLETED
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean StudyNCT05053152 · 2022-04-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).NCT05116189 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialNCT05050084 · 2021-12-06 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast CancerNCT04869943 · 2021-10-12 · 1 site observation
TERMINATED
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast CancerNCT04975308 · 2021-10-04 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related ComorbiditiesNCT05051579 · 2021-09-29 · 1 site observation
COMPLETED
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast CancerNCT04906395 · 2021-07-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialNCT04513717 · 2021-01-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy, Safety, and PK of LX9211 in Participants With Diabetic Peripheral Neuropathic PainNCT04455633 · 2020-09-03 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialNCT04134260 · 2020-04-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast CancerNCT04109066 · 2019-11-18 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney DiseaseNCT04026165 · 2019-07-24 · 1 site observation
COMPLETED
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerNCT03822468 · 2019-06-11 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - 2NCT03743064 · 2019-05-06 · 1 site observation
COMPLETED
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following SurgeryNCT03809000 · 2019-04-15 · 2 site observations
ACTIVE_NOT_RECRUITING
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump TherapyNCT03830281 · 2019-02-14 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskNCT03730662 · 2018-11-20 · 1 site observation
COMPLETED
A Study of LY3209590 in Participants With Type 2 Diabetes MellitusNCT03736785 · 2018-11-15 · 1 site observation
COMPLETED
Mylan Insulin Aspart StudyNCT03760068 · 2018-11-07 · 1 site observation
COMPLETED
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid TumorsNCT03662204 · 2018-08-23 · 1 site observation
COMPLETED
Radiation Therapy With or Without Apalutamide in Treating Patients With Recurrent Prostate Cancer, the BALANCE TrialNCT03371719 · 2018-06-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic AgentsNCT03434119 · 2018-02-20 · 1 site observation
TERMINATED
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic ControlNCT03386344 · 2018-02-19 · 1 site observation
TERMINATED
Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate CancerNCT03367702 · 2018-02-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCNCT03395197 · 2017-12-18 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin MonotherapyNCT03332771 · 2017-12-01 · 1 site observation
COMPLETED
Mylan Insulin Glargine StudyNCT03376789 · 2017-11-29 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.